TS-011,99.08%
产品编号:Bellancom-15603| CAS NO:339071-18-0| 分子式:C11H14ClN3O2| 分子量:255.70
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
TS-011
产品介绍 | TS-011 是 20-羟基二十碳四烯酸合成的选择性抑制剂。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | TS-011 is a selective inhibitor of 20-Hydroxyeicosatetraenoic acid synthesis. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
TS-011 is a selective inhibitor of 20-Hydroxyeicosatetraenoic acidsynthesis. TS-011 at a dose of 0.3 mg/kg inhibits the reduction in the blood flow velocities at 1 and 7 h after reperfusion (P<0.001). In addition, TS-011 inhibits the increase in the blood flow velocity at 24 h after reperfusion (P<0.01). TS-011 protects the microvascular perfusion area from the loss observed in vehicle-treated mice. TS-011, at a dose of 0.3 mg/kg, also reduces the infarct volume by almost 40% (P<0.05). In 9 dogs with delayed vasospasm, acute blockade of the synthesis of 20-HETE with TS-011 (1 mg/kg IV) significantly increases the diameter of the basilar artery by 39%. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
TS-011 is a selective inhibitor of 20-Hydroxyeicosatetraenoic acidsynthesis. TS-011 at a dose of 0.3 mg/kg inhibits the reduction in the blood flow velocities at 1 and 7 h after reperfusion (P<0.001). In addition, TS-011 inhibits the increase in the blood flow velocity at 24 h after reperfusion (P<0.01). TS-011 protects the microvascular perfusion area from the loss observed in vehicle-treated mice. TS-011, at a dose of 0.3 mg/kg, also reduces the infarct volume by almost 40% (P<0.05). In 9 dogs with delayed vasospasm, acute blockade of the synthesis of 20-HETE with TS-011 (1 mg/kg IV) significantly increases the diameter of the basilar artery by 39%. 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 250 mg/mL (977.71 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |
|